News

AstraZeneca's oncology sales hit $6.8B in first-quarter 2026, fueled by key cancer drugs. New launches and late-stage pipeline assets support growth.

The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts’ estimates.

Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

At the 24% federal bracket, a $1 million dividend portfolio generating roughly $45,000 in annual income can hand the IRS between $6,750 and $10,800 every year, depending on how much of that income is qualified versus ordinary. Inside a Roth IRA, that same income lands in your account untouched. This article walks through exactly what ... This Is What a $1 Million Dividend Portfolio Pays After Taxes

The rest of the stocks in the IHE ETF make it an unappealing way to play the pharma industry here.

AbbVie's shareholders can sleep easy.

Persistent inflation is likely to keep the Federal Reserve from cutting rates until well into 2027. Rising costs in services, housing, energy, and tariffs continue to keep inflation above the Fed’s 2% target, while the labor market remains strong enough to support wage pressures. Because of this, the Fed is expected to keep rates higher ... No Rate Cuts Until 2027? Grab These High-Yielding Safe Dividend Kings Now

Some investors may be wondering whether Johnson & Johnson at around US$225 per share still offers value, or if most of the opportunity is already reflected in the price. The stock is up 48.6% over the past year and 8.7% year to date, even though it has slipped 3.8% in the last week and 0.8% over the past month. This mixed performance may have some investors reassessing the balance between potential upside and risk. Recent news coverage has focused on Johnson & Johnson's position as a large,...

Johnson & Johnson (NYSE:JNJ) is included among the 15 Best Dividend Paying Stocks to Buy Right Now. Johnson & Johnson (NYSE:JNJ) and its subsidiaries develop, manufacture, and sell a broad range of healthcare products, giving the company a presence across multiple areas of the healthcare industry. The company’s dividend remains one of its biggest attractions […]

The income target is straightforward: $12,500 a month equals $150,000 a year, and the portfolio doing the work is $2.8 million. Dividing the income by the capital gives the math the whole article has to solve: a blended yield of roughly 5.4%. That number falls in the middle of the income-investing spectrum, which is why ... How to Build $12,500 a Month in Dividend Income From a $2.8 Million Portfolio Without Touching the Aggressive Tier

These 3 Dividend Kings combine decades of dividend growth with strong fundamentals, recession resistance, and long-term income potential

Nanobiotix (ENXTPA:NANO) has closed a global equity offering to fund continued development of its lead product candidate JNJ-1900 (NBTXR3). The raise followed promising early results from a Johnson & Johnson sponsored Phase 2 trial in stage 3 inoperable non small cell lung cancer, presented at ESTRO 2026. The company plans to use the new capital to progress its oncology pipeline, with a focus on JNJ-1900 (NBTXR3). For investors tracking ENXTPA:NANO, the combination of fresh equity funding...

High energy prices have investors worried about a recession; these businesses should survive the hit just fine.

Generating $5,000 per month in passive income works out to $60,000 annually, a level many retirees target to cover core expenses without relying heavily on Social Security or selling assets during market downturns. At a 6% portfolio yield, reaching that income level requires roughly $1 million invested. The harder question is not simply reaching the yield ... The Two Bucket Income Portfolio That Pays $5,000 a Month Plus a Cash Reserve to Survive 2008 Style Drawdowns

Walmart is facing short-term pressures that are leading investors to miss the long-term opportunity.

Johnson & Johnson (JNJ) reached $225.33 at the closing of the latest trading day, reflecting a -2.37% change compared to its last close.

Boston Scientific posted two of the top three Volume-to-Open Interest ratios during Thursday's trading session, a notable signal often associated with heightened market speculation. This unusual options activity suggests the medical devices giant could be a potential acquisition target. Here's a closer look at why.

The Vanguard High Dividend Yield Index Fund ETF Shares (NYSEARCA:VYM) is one of the simplest income vehicles in the market: it owns roughly 500 U.S. stocks that pay above-average dividends, weights them by market cap, and passes the cash through to shareholders. VYM tracks the FTSE High Dividend Yield Index, which excludes REITs and screens ... VYM Climbs 26% In a Year While Its Core Dividend Payers Extend Their Streaks

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

Passive income arrives on its own schedule, no effort required. Dividends keep landing in the brokerage account on a predictable schedule, regardless of headlines or market moves. High-yield, blue-chip dividend stocks offer something real estate and most alternative income vehicles cannot: liquidity and flexibility. You can buy and sell on a Tuesday morning, reinvest distributions ... Want $1,400 in Passive Income? Invest $10,000 Into These 4 Dividend Stocks

Partnership strategy has produced great pharma bargains—and left the company exposed.

The Congressional Budget Office (CBO) released a report this year containing one number that should change how every American near retirement thinks about income. Here's 3 dividend stocks to replace that lost income.

Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices.

The Vanguard Dividend Appreciation ETF (NYSEARCA:VIG) owns only companies with at least 10 consecutive years of dividend growth, screens out the highest yielders, and lets compounding work. VIG has returned 22% over the past year and 244% over the past decade, a track record that owes as much to its tech-heavy roster as to traditional ... Microsoft’s AI Spending Won’t Derail Dividend Safety Inside Vanguard’s VIG

The average brokerage recommendation (ABR) for Johnson & Johnson (JNJ) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss pressure.

Boston Scientific (BSX) previously commanded a premium valuation based on its transition toward a high-margin cardiovascular powerhouse, driven by its FARAPULSE Pulsed Field Ablation (PFA) system and WATCHMAN cardiac implant. In Q1 2026, the cardiovascular segment posted a strong 13.5% reported growth. However, intense competition from Medtronic (MDT) and Johnson & Johnson (JNJ) has challenged this hyper-growth thesis. Johnson & Johnson's Varipulse system integrates directly into the dominant CA

Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory.

Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook.

Johnson & Johnson seems to have perfected the art of the biotech deal. Rather than spending billions on acquisitions, it has built much of its pharma empire through partnerships that capture huge upside for bargain prices. A biotech partnership is a bit like an open relationship: Your partner can always fall in love with someone else.